Aug 18, 2020 | Member News, Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that Professor Jackie Hunter is to take the role of Chair in September 2020. Jackie is currently a Board Director...
Apr 20, 2020 | Member News, Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that Dr Hugo Villanueva is to join as Innovation and Business Development Director in May 2020. Hugo joins us from...
Jan 15, 2020 | Member News, Stevenage Bioscience Catalyst
The UK and the NHS are providing the right environment and infrastructure to allow innovative cell and gene therapies to reach patients. International companies recognise the appeal of the UK cell and gene therapy ecosystem and are sponsoring the majority of the UK...
Jan 13, 2020 | Member News, Stevenage Bioscience Catalyst
~Phase 2b dose range finding study showed rapid and highly significant reductions in the frequency of hot flashes (primary endpoint) for the full 12-week treatment period~ ~Reduction in hot flashes was associated with statistically significant improvements in quality...
Dec 19, 2019 | Member News, Stevenage Bioscience Catalyst
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces Syncona Ltd (Syncona) has made an $80.0 million (£61.1 million)[1] commitment in a Series C financing and has funded the first tranche of...
Dec 19, 2019 | Member News, Stevenage Bioscience Catalyst
Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster. The £1.2m Local Growth Fund investment will provide much-needed temporary accommodation for growing...
